Principia is committed to changing the drug development paradigm. The company's reversible covalent technology platform rapidly and reliably produces compounds with superior selectivity, enabling development of multiple product candidates with substantial commercial potential. Principia's platform can even be applied to high-value disease targets that are otherwise deemed "undruggable." As a result, Principia is ushering in a new chapter in the development of truly novel therapies with substantial clinical and commercial potential. The company is leveraging the broad utility of its platform to develop best-in-class inhibitors in a wide variety of indications with substantial unmet medical need. Initial areas of focus include inflammatory and autoimmune diseases and cancer.
In order to fully realize the value of its reversible covalent platform, Principia has built a team of exceptionally talented scientists and business leaders. Additionally, the company is enhancing its position as the dominant reversible covalent drug company with robust intellectual property, unparalleled in-house expertise, and exclusive academic collaborations.